In a method for producing a cell concentrate using a cell suspension treatment system including a storage container of a cell suspension, which has a solution inlet port, a circulation outlet port, and a circulation inlet port, a cell suspension treatment device for concentrating the cell suspension by separating liquid from the cell suspension by filtration, the device including a container having a cell suspension introduction port, a cell suspension lead-out port, and a filtrate outlet, which is filled with a hollow fiber separation membrane, a circulation circuit for concentrating the cell suspension while circulating the cell suspension between the storage container and the cell suspension treatment device, a collection container of a cell concentrate obtained by concentration, a collection path for feeding the cell concentrate to the collection container, an injection path for injecting a solution into the solution inlet port of the storage container, and a detecting unit.

The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.

Dialysis systems are disclosed comprising new fluid flow circuits. Systems may include blood and dialysate flow paths, where the dialysate flow path includes balancing, mixing, and/or directing circuits. Dialysate preparation may be decoupled from patient dialysis. Circuits may be defined within one or more cassettes. The fluid circuit fluid flow paths may be isolated from electrical components. A gas supply in fluid communication with the dialysate flow path and/or the dialyzer able to urge dialysate through the dialyzer and urge blood back to the patient may be included for certain emergency situations. Fluid handling devices, such as pumps, valves, and mixers that can be actuated using a control fluid may be included. Control fluid may be delivered by an external pump or other device, which may be detachable and/or generally rigid, optionally with a diaphragm dividing the device into first and second compartments.

In a method for producing a cell concentrate using a cell suspension treatment system including a storage container of a cell suspension, which has a solution inlet port, a circulation outlet port, and a circulation inlet port, a cell suspension treatment device for concentrating the cell suspension by separating liquid from the cell suspension by filtration, the device including a container having a cell suspension introduction port, a cell suspension lead-out port, and a filtrate outlet, which is filled with a hollow fiber separation membrane, a circulation circuit for concentrating the cell suspension while circulating the cell suspension between the storage container and the cell suspension treatment device, a collection container of a cell concentrate obtained by concentration, a collection path for feeding the cell concentrate to the collection container, an injection path for injecting a solution into the solution inlet port of the storage container, and a detecting unit.

The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.

A method for onsite hemorrhage control in trauma patients using a portable rapid autotransfusion device can involve recovering a first portion of patient blood from an extravascular space into a fluid reservoir of the device. A negative internal pressure can be applied to the blood. The blood can be conditioned, such as by oxygenating and removing carbon dioxide. The conditioned blood can be returned to the patient intravenously at a rate that matches the rate of blood recovery, ensuring that the net volume of returned blood is maintained substantially equal to the net volume of removed blood.

The present disclosure relates to methods of removing soluble NKG2D ligands, including soluble MICA, soluble MICB and soluble ULBP proteins, from blood to treat diseases characterized by abnormal levels of soluble NKG2D ligands. Further provided are systems and devices for carrying out the therapeutic methods.

Systems and methods for perfusing a treatment solution into the blood stream of particular organs while isolating those organs from the systemic vasculature as a whole. By deploying both collection and supply catheters, some having balloons on their distal ends, to particular locations within the body, various organs can be isolated so that the treatment solution can be delivered directly thereto. By isolating the organs, any side effects that may occur from a systemic introduction of the treatment solution are avoided. The method may be used to isolate not just organs, but specific tumors within certain organs for oncology treatment.

An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments. In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.

Filtering systems, methods, and devices, particularly adapted for apheresis of cellular bodies and more specifically for apheresis of circulating tumor cell bodies (CTCs) employs a cross-flow channel. Systems and methods as well as devices for such a system are described. Embodiments include a cylindrical filter that employs a thin micro-machined porous filter membrane with a regular array of pores and reliably pass blood while trapping CTCs.